Aurisco PharmaceuticalLtd Management
Management criteria checks 2/4
Aurisco PharmaceuticalLtd's CEO is Dingjun Chu, appointed in Jun 2017, has a tenure of 7.5 years. directly owns 0.81% of the company’s shares, worth CN¥69.89M. The average tenure of the management team and the board of directors is 7.5 years and 7.5 years respectively.
Key information
Dingjun Chu
Chief executive officer
CN¥1.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.8% |
| Management average tenure | 7.5yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
CEO
Dingjun Chu (51 yo)
7.5yrs
Tenure
CN¥1,713,284
Compensation
Mr. Dingjun Chu is General Manager and Director of Aurisco Pharmaceutical Co.,Ltd. since June 01, 2017.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 7.5yrs | CN¥1.71m | 0.81% CN¥ 69.9m | |
| Deputy GM & Director of Sales | 7.5yrs | CN¥1.29m | 0.044% CN¥ 3.8m | |
| Deputy GM & Director | 7.5yrs | CN¥1.75m | no data | |
| Board Secretary | 7.5yrs | CN¥1.13m | no data | |
| Deputy General Manager | 6.8yrs | CN¥906.76k | 0.062% CN¥ 5.3m |
7.5yrs
Average Tenure
51yo
Average Age
Experienced Management: 605116's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 7.5yrs | CN¥1.71m | 0.81% CN¥ 69.9m | |
| Deputy GM & Director | 4.6yrs | CN¥1.75m | no data | |
| Vice Chairman | 7.5yrs | CN¥76.12k | 31.71% CN¥ 2.7b | |
| Chairman of the Board | 7.5yrs | CN¥1.36m | 37.81% CN¥ 3.3b | |
| Director | 7.5yrs | CN¥1.08m | 2.06% CN¥ 177.5m | |
| Chairman of the Supervisory Board | 7.5yrs | no data | 0.81% CN¥ 69.9m | |
| Supervisor | 7.5yrs | no data | no data |
7.5yrs
Average Tenure
58yo
Average Age
Experienced Board: 605116's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 07:23 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aurisco Pharmaceutical Co.,Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |
| Wenxin Yu | Haitong International Research Limited |